$10 Billion Deal, page-1425

From what I understand, the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle this year did not mention BIT225.

Which is a shame, given BIT seems to promises 1st first line reduction in acquiescent HIV infected cells whilst delivered adjuvant with ART.

Further it contends that the following largely unmet market needs might be met:

BIT225 may impact on macrophage associated immune activation
BIT225 is able to cross the blood-brain barrier, with potential to treat HIV-associated neurocognitive disorder (HAND)

From what I understand of the conference immune system and inflammatory effects of residual virus, e.g. in the brain, is becoming large unmet need given ART is now so successful that those with HIV are now - lets just say it - are becoming old folks!

I am not a holder but I would be interested in considering purchase if the trials undertaken in BIT225 have some compelling impact in both.

Can any one point me to any scientific points on this?

Thank you.